ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Cereblon E3 Ubiquitin Ligase Modulating Drug BMS-986506

Its studies are mostly in Carcinoma, Renal Cell, led by Bristol-Myers Squibb.

Furthest: phase 1, since Sep 25, 20251 company-led study, 1 open or runningNext primary completion: May 3, 2030 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb11 open or runningphase 1since Sep 25, 2025Sep 25, 2025May 3, 2030phase 1 · NCT07195682
  • Named in Bristol-Myers Squibb’s own pipeline as BMS-986506, phase 1, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 25, 2025First study: phase 1 study in Carcinoma, Renal CellFirst studyNCT07195682 · 281 planned · United States, Canada, France and more

Ahead

  1. May 3, 2030Primary completion: phase 1 study in Carcinoma, Renal CellNCT07195682

TargetBeta

“A modulator of the E3 ubiquitin ligase complex containing cereblon (CRL4-CRBN E3 ubiquitin ligase), with potential antineoplastic activity. Upon administration, cereblon E3 ubiquitin ligase modulating drug BMS-986506 specifically targets and binds to cereblon (CRBN), thereby affecting the ubiquit…”NCIt, read by Claude

Other programs on CRBN

ProgramCompanyFurthest phaseStudies
LenalidomideruleBristol-Myers Squibbphase 4109
pomalidomideruleBristol-Myers Squibbphase 451
mezigdomideBristol-Myers Squibbphase 312
golcadomideBristol-Myers Squibbphase 311
HRS-3738Jiangsu HengRui Medicinephase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07195682Carcinoma, Renal Cell · United States, Canada, France and more1RecruitingMay 3, 2030281

How it is read

Names in the registry

  • “BMS-986506”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.